Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2566683 | 0.86 | SIGMAR1 (0.78) | SIGMAR1LTA4HPTGS1PTGS2HRH3 | |
| SCHEMBL3190605 | 0.85 | SIGMAR1 (0.61) | SIGMAR1LTA4HPTGS1PTGS2HRH3 | |
| SCHEMBL7362580 | 0.84 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL27935616 | 0.84 | SIGMAR1 (0.67) | SIGMAR1F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL26378417 | 0.84 | CHRNB4 (0.68) | SIGMAR1NPC1RAB9AACHELTA4H | |
| SCHEMBL27935608 | 0.83 | SIGMAR1 (0.70) | SIGMAR1ACHEF2KDM4EALDH1A1 | |
| SCHEMBL27935609 | 0.83 | SIGMAR1 (0.70) | SIGMAR1ACHELTA4HPTGS1PTGS2 | |
| SCHEMBL2562011 | 0.83 | SIGMAR1 (0.69) | SIGMAR1LTA4HPTGS1PTGS2HRH3 | |
| SCHEMBL22126801 | 0.82 | SIGMAR1 (0.68) | SIGMAR1ACHEF2KDM4EALDH1A1 | |
| SCHEMBL2759959 | 0.82 | SIGMAR1 (0.68) | SIGMAR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994000-B1 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2017-08-23 | — | — | EP | disclosed |
| EP-1994000-B1 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2017-08-23 | — | — | EP | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| EP-2027124-B1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| CN-101415679-A | Water-soluble CC-1065 analogs and conjugates thereof | SINTAGAR B V (NL) | 2009-04-22 | — | — | CN | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008054956-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | SIGMAR1 4093/4885NPC1 3703/4885POLB 1053/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | SIGMAR1 1565/4885NPC1 2557/4885POLB 2814/4885 |
| US-20120252761-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | SIGMAR1 4093/4885NPC1 3703/4885POLB 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.